- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00861185
Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma
July 8, 2011 updated by: Icagen
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Safety and Efficacy of Four Weeks of Oral Senicapoc Administration on Exercise-Induced Asthma
The purpose of this study is to determine whether 4 weeks of dosing with senicapoc alleviates exercise induced asthma symptoms.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Based on the unmet medical need for new agents in the treatment of asthma and the role of KCa3.1 in the function of several different cell types involved in the inflammatory response, and the effects seen in an animal model of allergic asthma, it is reasonable to explore the utility of senicapoc, a KCa3.1 blocker, as a novel treatment of asthma.
This study will test the ability of senicapoc to alleviate bronchospasm induced by an exercise challenge in subjects with asthma.
Exercise challenge studies have been conducted for many currently approved asthma medications.
Exercise challenge studies provide a controlled environment and test conditions to investigate the potential usefulness of novel study drugs for the treatment of asthma.
This study will be the first to test the ability of senicapoc to reduce airway bronchospasm after exercise challenge, which is one clinically important manifestation of asthma seen in patients.
In summary, with a demonstrated safety profile across a wide range of doses in humans and efficacy in an animal model of allergic bronchospasm and hyper-responsiveness, the initiation of exploratory studies of senicapoc for treatment of asthma is justified.
Study Type
Interventional
Enrollment (Actual)
69
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Huntington Beach, California, United States, 92647
-
Orange, California, United States, 92868
-
-
Illinois
-
Normal, Illinois, United States, 61761
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
-
-
Missouri
-
St. Louis, Missouri, United States, 63141
-
-
New Jersey
-
Skillman, New Jersey, United States, 08558
-
-
New York
-
North Syracuse, New York, United States, 13212
-
-
Ohio
-
Canton, Ohio, United States, 44718
-
-
Washington
-
Seattle,, Washington, United States, 98105
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Able and willing to give written informed consent to participate in the study as HIPAA authorization;
- Clinically acceptable medical history, physical examination, 12 lead ECG, vital signs, and clinical laboratory tests
- History of physician-diagnosed asthma according to Global Initiative for Asthma, AND exercise-induced asthma/ bronchoconstriction;
- Current treatment for asthma with short-acting inhaled beta-2-agonist ONLY;
- Baseline FEV1 >65% of predicted at Screen Visit 1;
- A 20% or greater drop in FEV1 following exercise challenge on at least two separate occasions prior to enrollment;
- Non-smoker (refrained from any tobacco usage, or any products containing nicotine, for 6 months prior to Day 1);
Exclusion Criteria:
- Subject who has experienced any allergic reaction to a drug which, suggests an increased potential for a hypersensitivity to senicapoc (e.g., clotrimazole);
- Previous ingestion of senicapoc (ICA-17043)
- Pregnant or lactating female;
- Condition that might interfere with the absorption, distribution, metabolism, and/or excretion of drugs; subjects who have had any previous gastrointestinal surgery, except appendectomy or cholecystectomy (if performed more than 90 days prior to Screening Visit 1) or a history of clinically significant active cardiovascular, neurologic, endocrine, hepatic, or renal disorders;
- Infectious illness, e.g. acute bacterial, acute and chronic parasitic, fungal infection or viral infection within 6 weeks prior to Screening Visit 1 or between Screening Visit 1 and Day 1 (Randomization).
- Treatment for conditions other than asthma with systemic corticosteroids within 1 month prior to Visit 1.
- Asthma exacerbation having necessitated treatment with inhaled corticosteroids within 6 weeks prior to study Screening Visit 1.
- History of severe asthma as defined by use of oral/injectable corticosteroids within the last 3 months and/or more than two bursts in the last year.
- Undergoing desensitization therapy unless on a maintenance dose for at least 3 months prior to entry and will continue as such throughout study participation.
- History of chronic pulmonary diseases other than asthma.
- Considering or scheduled to undergo any surgical procedure during the duration of the study;
- Ingestion of any investigational medication within 30 days prior to Screening Visit 1;
- A positive plasma alcohol, or urine cotinine test at Screening Visit 1;
Use of the following asthma medications for the stated period prior to Screening Visit 1 and throughout the study:
- Oral or parenteral corticosteroids within 3 months prior to Screening Visit 1
- Inhaled corticosteroids (ICS) (e.g., budesonide, fluticasone propionate) within 1 month prior to Screening Visit 1
- long acting beta agonists; leukotriene receptor antagonists; or anti-cholinergic agents (e.g. tiotropium) within the 2 weeks prior to Screening Visit;
- Use of antihistamines within 3 days prior to Screening Visit 1;
- Has a >10 pack-year history of smoking;
- Hypertension at screen (BP > 150/90), if deemed by Investigator to be unfit to complete exercise challenge testing;
- Screen QTc > 450 msec or ECG not suitable for QT measurement (e.g., poorly defined termination of T-wave);
- After exercise challenge test, subject not recovering to at least 90% of baseline FEV1 following administration of short-acting beta-2-agonist.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
Placebo looks identical to active study medication and will be dosed according to the same dosing regimen
|
EXPERIMENTAL: Senicapoc
|
Loading Dose: 80 mg twice daily x 3 days Maintenance Dose: 40 mg daily for remainder of the treatment period (total 4 weeks)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The change from baseline in the maximal percentage decrease in forced expiratory volume in one second (FEV1) after exercise
Time Frame: Week 2 and Week 4
|
Week 2 and Week 4
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
- Area under the curve (AUC) for FEV1 after exercise challenge, - the length of time for recovery of FEV1 after exercise challenge, - changes in non-challenge pulmonary function tests, and an asthma control questionnaire.
Time Frame: Week 2 and Week 4
|
Week 2 and Week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Jonathon Stocker, Ph.D., Icagen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2009
Primary Completion (ACTUAL)
July 1, 2009
Study Completion (ACTUAL)
September 1, 2009
Study Registration Dates
First Submitted
March 12, 2009
First Submitted That Met QC Criteria
March 12, 2009
First Posted (ESTIMATE)
March 13, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
July 14, 2011
Last Update Submitted That Met QC Criteria
July 8, 2011
Last Verified
July 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICA-17043-18
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Exercise Induced Asthma
-
Johann Wolfgang Goethe University HospitalCompleted
-
Forest LaboratoriesCompleted
-
Universita di VeronaCompleted
-
Indiana UniversityRecruitingExercise Induced Bronchospasm | Exercise Induced AsthmaUnited States
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
-
Brunel UniversityKarolinska InstitutetUnknown
-
Skane University HospitalSwedish Heart Lung FoundationCompletedRespiratory Function Tests
-
Johann Wolfgang Goethe University HospitalCompletedExercise Induced Asthma | Exercise Induced Pharyngeal CollapseGermany
Clinical Trials on senicapoc
-
IcagenCompletedAtopic AsthmaUnited Kingdom
-
University of AarhusOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsUnknownCOVID | ARDS, HumanDenmark
-
University of California, DavisRecruitingAlzheimer Disease | Mild Cognitive ImpairmentUnited States
-
Boston Children's HospitalCompleted